No problem. This is the biotech play everyone is holding on to in hopes that it's going to pay better than DNDN and pther recent ones.
It's imprtant to note that the HEB insiders are VERY confident that Ampligen will be approved. Especially given the wording in the last PR about why they went out to raise more capital:
These financings were conducted to generate additional capital to fund the final development and introduction of Ampligen, for Chronic Fatigue Syndrome, in the US market. Wayne Pambianchi, Executive Director of The Sage Group, said, "HemispherX's success in closing this important financing in this troubled financial market, is a clear reflection of the perceived importance of their Ampligen technology in a broad range of immunological applications."
News 
Market Data 
Discover 
